GlobeNewswire

ESDS Selects Juniper Networks to Power Future-Ready Cloud in India

Dela

ESDS deploys Juniper's high-performing automated networking solutions to optimize cloud application delivery for maximum speed and scalability

BANGALORE, India, July 10, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE:JNPR), an industry leader in automated, scalable and secure networks, today announced that ESDS, a managed data center service and auto-scalable cloud solution provider, has successfully implemented Juniper's high-performing networking solutions, including the QFX 5100EX 4550 and MX 104, which have  enabled rapid and secure cloud application delivery to their customers.

With ESDS experiencing an increase in workloads due to a fast growing customer base, the organization required a high-performance, low latency network that could help them securely deliver cloud applications without risk of delay or disruption. Having a reliable network is especially essential given that a majority of ESDS's customers are from critical sectors, such as government and financial services industries, which demand consistent high-performance and uninterrupted access to their applications.

To address this, ESDS selected Juniper Networks to help optimize, automate and secure its cloud application delivery infrastructure. Through the deployment of Juniper's carrier grade operating system, Junos OS, ESDS has also streamlined their operations and improved network management while reducing their total cost of ownership (TCO) by 20 percent, even while experiencing traffic growth of over 50 percent year-on-year.

Today, Juniper powers more than 90 percent of the organization's network infrastructure, helping ESDS drive greater digitization of data storage and processing capabilities across all its markets, particularly within infrastructure development and nation building. In fact, ESDS's accomplishments have included significant contributions to the Indian government's efforts in bringing the Pune Smart City vision to life, all while providing greater flexibility and superior up-time for citizen-centric online services.

With ESDS planning major expansions to Bangalore and other key cities in the near future, ESDS has selected Juniper as their networking partner to power their cloud transformation as they create a secure, scalable and automated multicloud environment for their customers.

News Highlights

  • Optimizing network scalability: The high-performance QFX5100 was deployed at the core by ESDS for their Mumbai and Nashik data centers, allowing for optimized application delivery, alongside the strong scalability required as part of their business operations.
  • Ease of network management: Leveraging the advanced capabilities of the compact, high-density EX4550 as the top-of-rack switch and the powerful MX104 Universal Routing Platform at their data-center edge, the deployment has improved network management by providing highly granular telemetry data, which aids in network monitoring, troubleshooting and planning activities. Additionally, Juniper's Virtual Chassis feature allows ESDS to manage multiple elements as a single device.
  • Increased operational efficiencies:  Junos OS as a common operating platform powering ESDS's entire Juniper deployment has greatly simplified, streamlined and automated network management. With Junos OS supported on the QFX, EX and MX platforms, ESDS can schedule software upgrades and configuration checks all on one interface, which frees up valuable time and resources, resulting in significant operational efficiencies and savings.   

Supporting Quotes

"As one of the leading cloud service providers in India, we were able to create our own patented vertical auto-scaling technology on our cloud platforms, thereby enabling a scalable cloud infrastructure. With this innovation in place, we needed a network that could support our cloud technology and Juniper helped us achieve that - all while ensuring that floating virtual machines between multiple data centers were operated with the highest levels of security."

- Piyush Somani, Managing Director, ESDS Software

"ESDS is a strong player with a proven track record in the cloud and automation space, and we are proud to have been selected to power their network. Their impressive pace of growth in the past few years is a reflection of the immense potential and success for cloud-based solutions in India. Coupled with our commitment to simplifying the journey for customers toward a secure and automated multicloud, we are eager to continue our partnership with ESDS to support their expansion in building a progressive and future-ready cloud for India."

- Ramesh Narasimhan, Sales Director, India, Juniper Networks

Additional Resources:

About Juniper Networks

Juniper Networks simplifies the complexities of networking with products, solutions and services in the cloud era to transform the way we connect, work and live. We remove the traditional constraints of networking to enable our customers and partners to deliver automated, scalable and secure networks that connect the world. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on TwitterLinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper and Junos are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

 
Media Relations:
Amanda Seow
Juniper Networks
+65 6714 2408
amandase@juniper.net



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Juniper Networks via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum